Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial.

Takuji Iwase,Shigehira Saji,Kotaro Iijima,Kenji Higaki,Shoichiro Ohtani,Yasuyuki Sato,Yasuo Hozumi,Yoshie Hasegawa,Yasuhiro Yanagita,Hiroyuki Takei,Maki Tanaka,Hideji Masuoka,Masahiko Tanabe,Chiyomi Egawa,Yoshifumi Komoike,Toshitaka Nakamura,Hiroshi Ohtsu,Hirofumi Mukai

Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2023）

引用 1|浏览27

暂无评分

摘要

Continuing adjuvant anastrozole for an additional 5 years after 5 years of initial treatment with anastrozole or tamoxifen followed by anastrozole was well tolerated and improved DFS. Although no difference in overall survival was observed as in other trials, extended anastrozole therapy could be one treatment choice in postmenopausal patients with hormone receptor-positive breast cancer.

查看译文

关键词

postoperative adjuvant anastrozole,receptor–positive breast cancer,breast cancer,open-label

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要